Drug Database
ER

erythropoietin beta (CinnaPoietin ß / CinnaPoietin)

✓ Approved

Cinnagen Co · EPOR · Recombinant Proteins

What is erythropoietin beta?

erythropoietin beta is a recombinant proteins developed by Cinnagen Co. It is approved for therapeutic indications via injectable (others) or intravenous (iv) or subcutaneous injection.

Drug Profile

Brand NamesCinnaPoietin ß, CinnaPoietin
CompanyCinnagen Co
Drug ClassRecombinant Proteins
Molecular TargetEPOR
RouteInjectable (Others), Intravenous (IV), Subcutaneous Injection
StatusApproved
Sources: ClinicalTrials.gov, Cinnagen Co

Mechanism of Action

Molecular Targets

erythropoietin beta acts on 1 molecular target:

EPORerythropoietin receptor (EPO-R)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

erythropoietin beta is developed for 2 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Blood and lymphatic system disordersAnaemia✓ Approved
Blood and lymphatic system disordersNephrogenic anaemia✓ Approved

Related Research Articles

PubMedImmunological reviews2026-10-15

Oxidative Stress, Post-Translational Modifications, and Type 1 Diabetes Pathogenesis.

Winstead Colleen J CJ, Hodel Miki M, Tse Hubert M HM

Type 1 diabetes (T1D) is an organ-specific autoimmune disease that destroys insulin-producing beta-cells. Insulin is a vital hormone for regulating glycemia that often undergoes post-translational modifications during processing from pre-proinsulin to biologically active insulin. While necessary for proper glucose homeostasis, insulin is also an autoantigen recognized by autoreactive T cells in T1D. Cellular stress pathways including endoplasmic reticulum stress and oxidative stress mediated by an increase in reactive oxygen species (ROS) synthesis and/or a concomitant decrease in antioxidant function can further drive post-translational modifications of various autoantigens in T1D including insulin. Innate immune-derived ROS generation is an essential frontline defense against microbial infections, but ROS can also function as signaling intermediates to properly stimulate T cell responses. Oxidative stress-induced post-translational modifications are thought to trigger autoreactive T cells in T1D by generating novel neoepitopes, eliciting epitope spreading, or enhancing autoantigen interactions with antigen-presenting cells. With the current technology, detecting post-translationally modified proteins is challenging. In this review, we will explore the role of ROS and other post-translational modifications involved in T1D. We will also discuss islet transplantation strategies being used for patients with T1D including novel cell sources for beta-cell replacement and management of oxidative stress after transplantation.

PMID 42876362
Read full article →
PubMedAmerican journal of therapeutics2026-10-15

The Evolving Landscape of Hypertrophic Cardiomyopathy Treatment: Are Guidelines Keeping Pace?

Shusterman Vlad V, Salamatbad Gidon G, Weintraub Spencer S, Wharton Ronald R

Hypertrophic cardiomyopathy (HCM) is a common inherited cardiovascular disorder associated with morbidity. Rapid advances in therapeutics-particularly the emergence of cardiac myosin inhibitors (CMIs)-suggest that current management guidelines are lagging best practices. Cardiac myosin inhibitors have revolutionized the management of patients with obstructive HCM. Patients with nonobstructive HCM have had limited therapeutic options historically; however, the recently published ACACIA-HCM trial demonstrated significant benefit in these patients and may represent a new treatment option in these patients, although more long-term data and research are needed in this population. A literature review was performed using PubMed/MEDLINE, Google Scholar, society guidelines, and recently published clinical trials evaluating HCM, cardiac myosin inhibitors, beta blockers, calcium channel blockers, septal reduction therapy, and emerging therapies for obstructive and nonobstructive HCM. Historically, HCM management has centered on negative inotropic/chronotropic agents to alleviate left ventricular outflow tract obstruction by decreasing the force of contraction and increasing diastolic filling time. The introduction of CMIs represents a paradigm shift by directly targeting the underlying hypercontractility, representing the first therapy specifically designed to treat obstructive HCM, obviating the need for earlier agents, which had limited data and at best modest therapeutic benefit. There may finally be an available treatment for diastolic heart failure in patients with nonobstructive HCM with myosin inhibition, as results from a recent trial ACACIA-HCM were favorable. Furthermore, ongoing investigations are exploring novel approaches such as metabolic modulators. The management of HCM is undergoing substantial transformation, yet guideline recommendations continue to prioritize beta blockers as first-line therapy despite mounting evidence supporting CMIs. Although treatment strategies for obstructive HCM have evolved significantly, optimal approaches for nonobstructive disease remain unclear. Addressing this gap represents a critical priority for future research.

PMID 42875832
Read full article →
PubMedBasic and clinical andrology2026-10-15

Alterations in urinary microbiota composition and function in men with Asthenozoospermia: a case-control study.

Pan Yang Y, Wang Shangren S, Cao Tingshuai T, Li Bing B et al.

Asthenozoospermia (AZS) is a leading cause of male-factor infertility, yet the contribution of the urinary microbiota to sperm motility remains poorly defined, because previous work has focused almost exclusively on the seminal and gut microbiota. Here we used 16S rRNA gene sequencing to characterize the composition and functional profiles of the urinary microbiota in men with AZS and in fertile controls. Isolated AZS and age-matched fertile controls were enrolled, and urinary specimens from participants were sequenced successfully. Alpha diversity of the urinary microbiota did not differ between the two groups. In contrast, beta diversity analysis revealed a statistically significant difference in overall community structure, although the group effect was modest in magnitude (PERMANOVA on Bray-Curtis dissimilarities, R2 = 0.13, p = 0.001). Eighteen genera differed significantly in relative abundance. Porphyromonas, Corynebacterium, and Finegoldia were more abundant in men with AZS, whereas Blautia and Bacteroides were more abundant in controls. Predicted functional analysis identified multiple metabolic and genetic-information-processing pathways that differed between the groups, including replication and repair modules, peptidoglycan biosynthesis, one-carbon pool by folate, and nicotinate and nicotinamide metabolism. It appears that men with AZS exhibit altered urinary microbiota structure and predicted functional profile. These associations extend the microbiome-male-infertility axis beyond the seminal and gut compartments and may inform biomarker discovery and microbiome-modulating strategies, although longitudinal and mechanistic studies are required to establish causality.

PMID 42875745
Read full article →
PubMedFrontiers in plant science2026-10-15

A beta-tubulin-based qPCR assay for monitoring of Peronospora variabilis and disease progression in quinoa.

Palma-Encinas Valeria D VD, Yaniquez Vedia Jorge F JF, Claure-Mollo Micaela M, Vasquez-Vargas Keveen F KF et al.

Peronospora variabilis, the causal agent of downy mildew disease, is an important pathogen affecting quinoa production worldwide. Conventionally its detection relies primarily on visual scoring of chlorosis, at times complemented by PCR-based assays targeting the cytochrome oxidase subunit 2 (cox2) or internal transcribed spacer (ITS) regions. In this study, we evaluated three candidate qPCR markers (cox2), NADH dehydrogenase subunit 1 (nad1), and β-tubulin (btub) and developed a btub-based qPCR assay for quantifying P. variabilis during infection. Among the three markers, the btub assay showed the best overall performance, with amplification efficiencies of 99-111% and coefficients of determination (R²) above 0.99 and was therefore selected for pathogen quantification. The btub-based qPCR assay enabled quantification of P. variabilis throughout disease progression and revealed three distinct phases of pathogen accumulation. Pathogen DNA accumulation was compared with chlorophyll, carotenoids, phenolics, betalains, and a rapid Red, Green, and Blue (RGB) colorimetric analysis. The pathogen accumulation curves revealed similar infection dynamics among cultivars previously classified as tolerant or susceptible, suggesting that differences in previously reported cultivar tolerance are not readily explained by pathogen accumulation in the sampled leaf tissue alone. This work introduces a qPCR assay targeting btub gene for quantifying P. variabilis in host plants, addressing the current incompleteness of validated molecular tools for tracking pathogen DNA accumulation during disease development and providing a valuable tool for linking pathogen growth with host physiological responses in future studies on plant-pathogen interactions.

PMID 42876726
Read full article →
PubMedJournal of gastroenterology and hepatology2026-10-15

The Role of Gut Microbiota in Chronic Constipation and the Therapeutic Potential of Fecal Microbiota Transplantation.

Wang Xinxin X, Wang Lu L, Liu Yuedong Y

This study investigates the relationship between gut microbiota dysbiosis and chronic constipation (CC) and evaluates the therapeutic efficacy of fecal microbiota transplantation (FMT) in restoring microbial homeostasis and metabolic function. We retrospectively analyzed existing before-after clinical data from 206 patients with CC who received FMT. No placebo or case-control group was included. Gut microbiota profiles were analyzed before and after FMT using 16S rRNA sequencing. Alpha and beta diversity indices were calculated to assess microbial community evolution. Gas chromatography-mass spectrometry (GC-MS) was employed to quantify short-chain fatty acids (SCFAs). Patients were stratified into butyrate-high and butyrate-low metabolic subtypes using a partitioning around medoids (PAM) algorithm based on pre-transplant butyrate levels. Clinical severity was independently defined using Rome IV criteria, CSBM, BSFS, and PAC-SYM. FMT significantly increased microbial α-diversity and shifted the community structure toward that of healthy donors. Post-transplant, the Bacteroidetes/Firmicutes ratio decreased from 46.8% to 38.9%, with a marked enrichment of beneficial taxa such as Faecalibacterium, Akkermansia, and Bifidobacterium. These shifts correlated with a significant rise in SCFA concentrations, particularly acetic and butyric acids. Butyrate deficiency was characterized by broader SCFA deficiencies and fragmented microbial networks. Multivariable binary logistic regression identified Faecalibacterium, ACE index, and acetic acid as independent predictors of clinically defined constipation severity. FMT was associated with increased microbial diversity, restoration of SCFA-producing taxa, and increased SCFA concentrations in patients with CC. These changes accompanied improvements in CSBM, BSFS, PAC-SYM, and PAC-QOL.

PMID 42876317
Read full article →
PubMedFrontiers in pharmacology2026-10-15

Chicoric acid-rich extract of Cichorium intybus seeds (CAREOCI) preserves pancreatic β-cell function under glucotoxic stress through modulation of MAFA, DYRK1A, cell cycle, apoptosis, and mitochondrial dysfunction.

Khan Anish Murtaja Alam AMA, Chandra Kailash K, Choudhary Furqan F, Alam Aftab A et al.

Progressive decline in functional pancreatic β-cell mass is a key pathological feature of type 2 diabetes mellitus (T2DM), highlighting the need for therapies that preserve and regenerate β-cells. This study investigated the preservative effects of a chicoric acid-rich aqueous extract of Cichorium intybus seeds (CAREOCI) under glucotoxic conditions (25 mM glucose) in pancreatic β-cells. Phytochemical standardisation by HPTLC, HPLC, and LC-MS/MS confirmed chicoric acid is the principal constituent present in CAREOCI. A molecular docking study identified DYRK1A is a one of the key target (-8.72 kcal/mol) of chicoric acid for β-cell regeneration. In glucotoxic MIN 6 β-cells, CAREOCI significantly enhanced glucose-stimulated insulin secretion, restored antioxidant status, reduced intracellular ROS, and suppressed IL-1β and TNF-α. CAREOCI also reduced apoptosis, attenuated caspase-3/7 activity, preserved normal nuclear morphology, restored mitochondrial membrane potential, and promoted autophagy through increased acidic vesicular organelles. Cell-cycle analysis indicated a trend toward increased S-phase population, suggesting enhanced β-cell proliferation. At the molecular level, CAREOCI downregulated DYRK1A, NF-κB, mTOR, and CHOP while upregulating MAFA, PDX1, PAX6, and NKX6.1, supporting β-cell survival and preservation. Compared with purified chicoric acid, CAREOCI consistently exhibited greater efficacy, indicating potential complementarity among its phytoconstituents. CAREOCI protects pancreatic β-cells through coordinated antioxidant, anti-inflammatory, anti-apoptotic, mitochondrial-protective, autophagy-promoting effects, supporting beta cell preservation and function under glucotoxicity condition supporting its potential as a phytopharmaceutical for T2DM.

PMID 42876685
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about erythropoietin beta